{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:44:07Z","timestamp":1790837047515,"version":"4.1.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-008274"],"award-info":[{"award-number":["INV-008274"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Anti-malarial drugs play a critical role in reducing malaria morbidity and mortality, but their role is mediated by their effectiveness. Effectiveness is defined as the probability that an anti-malarial drug will successfully treat an individual infected with malaria parasites under routine health care delivery system. Anti-malarial drug effectiveness (AmE) is influenced by drug resistance, drug quality, health system quality, and patient adherence to drug use; its influence on malaria burden varies through space and time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study uses data from 232 efficacy trials comprised of 86,776 infected individuals to estimate the artemisinin-based and non-artemisinin-based AmE for treating falciparum malaria between 1991 and 2019. Bayesian spatiotemporal models were fitted and used to predict effectiveness at the pixel-level (5\u00a0km\u2009\u00d7\u20095\u00a0km). The median and interquartile ranges (IQR) of AmE are presented for all malaria-endemic countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The global effectiveness of artemisinin-based drugs was 67.4% (IQR: 33.3\u201375.8), 70.1% (43.6\u201376.0) and 71.8% (46.9\u201376.4) for the 1991\u20132000, 2006\u20132010, and 2016\u20132019 periods, respectively. Countries in central Africa, a few in South America, and in the Asian region faced the challenge of lower effectiveness of artemisinin-based anti-malarials. However, improvements were seen after 2016, leaving only a few hotspots in Southeast Asia where resistance to artemisinin and partner drugs is currently problematic and in the central Africa where socio-demographic challenges limit effectiveness. The use of artemisinin-based combination therapy (ACT) with a competent partner drug and having multiple ACT as first-line treatment choice sustained high levels of effectiveness. High levels of access to healthcare, human resource capacity, education, and proximity to cities were associated with increased effectiveness. Effectiveness of non-artemisinin-based drugs was much lower than that of artemisinin-based with no improvement over time: 52.3% (17.9\u201374.9) for 1991\u20132000 and 55.5% (27.1\u201373.4) for 2011\u20132015. Overall, AmE for artemisinin-based and non-artemisinin-based drugs were, respectively, 29.6 and 36% below clinical efficacy as measured in anti-malarial drug trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provides evidence that health system performance, drug quality and patient adherence influence the effectiveness of anti-malarials used in treating uncomplicated falciparum malaria. These results provide guidance to countries\u2019 treatment practises and are critical inputs for malaria prevalence and incidence models used to estimate national level malaria burden.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12936-020-03446-8","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T12:03:58Z","timestamp":1603195438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Global estimation of anti-malarial drug effectiveness for the treatment of uncomplicated Plasmodium falciparum malaria 1991\u20132019"],"prefix":"10.1186","volume":"19","author":[{"given":"Giulia","family":"Rathmes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan F.","family":"Rumisha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim C. D.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Twohig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Python","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita K.","family":"Nandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne H.","family":"Keddie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma L.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Rozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry S.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth G.","family":"Chestnutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Battle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina S.","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punam","family":"Amratia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Arambepola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Bertozzi-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasmin L.","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe J.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Gething","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"3446_CR1","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","volume":"392","author":"GBD 2017 Mortality Collaborators","year":"2018","unstructured":"GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736\u201388.","journal-title":"Lancet"},{"key":"3446_CR2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","volume":"390","author":"GBD 2016 Mortality Collaborators","year":"2017","unstructured":"GBD 2016 Mortality Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151\u2013210.","journal-title":"Lancet"},{"key":"3446_CR3","volume-title":"World malaria report 2014","author":"WHO","year":"2014","unstructured":"WHO. World malaria report 2014. Geneva: World Health Organization; 2014."},{"key":"3446_CR4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(13)62566-0","volume":"383","author":"AM Noor","year":"2014","unstructured":"Noor AM, Kinyoki DK, Mundia CW, Kabaria CW, Mutua JW, Alegana VA, et al. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000\u201310: a spatial and temporal analysis of transmission intensity. Lancet. 2014;383:1739\u201347.","journal-title":"Lancet"},{"key":"3446_CR5","volume-title":"Key points: World malaria report","author":"WHO","year":"2017","unstructured":"WHO. Key points: World malaria report. Geneva: World Health Organization; 2017."},{"key":"3446_CR6","volume-title":"Chemotherapy of malaria. Report of a WHO scientific group","author":"WHO","year":"1967","unstructured":"WHO. Chemotherapy of malaria. Report of a WHO scientific group. Geneva: World Health Organization; 1967."},{"key":"3446_CR7","volume-title":"Chemotherapy of malaria","author":"WHO","year":"1986","unstructured":"WHO. Chemotherapy of malaria. Geneva: Wolrd Health Organization; 1986."},{"key":"3446_CR8","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"3446_CR9","volume-title":"List of Maps. Malaria endemic countries","author":"CDC","year":"2018","unstructured":"CDC. List of Maps. Malaria endemic countries. Atlanta: Centers for Disease Control and Prevention; 2018."},{"key":"3446_CR10","volume-title":"WHO certifies Paraguay malaria-free","author":"WHO","year":"2018","unstructured":"WHO. WHO certifies Paraguay malaria-free. Geneva: World Health Organization; 2018."},{"key":"3446_CR11","volume-title":"World malaria report 2019","author":"WHO","year":"2019","unstructured":"WHO. World malaria report 2019. Geneva: World Health Organization; 2019."},{"key":"3446_CR12","volume-title":"World malaria report 2017","author":"WHO","year":"2017","unstructured":"WHO. World malaria report 2017. Geneva: World Health Organization; 2017."},{"key":"3446_CR13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0140-6736(09)61349-0","volume":"374","author":"U Samarasekera","year":"2009","unstructured":"Samarasekera U. Countries race to contain resistance to key anti-malarial. Lancet. 2009;374:277\u201380.","journal-title":"Lancet"},{"key":"3446_CR14","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619\u201320.","journal-title":"N Engl J Med"},{"key":"3446_CR15","volume-title":"Emergence and spread of artemisinin resistance calls for intensified efforts to withdraw oral artemisinin-based monotherapy from the market","author":"WHO","year":"2014","unstructured":"WHO. Emergence and spread of artemisinin resistance calls for intensified efforts to withdraw oral artemisinin-based monotherapy from the market. Geneva: World Health Organization; 2014."},{"key":"3446_CR16","volume-title":"Drug resistance in malaria","author":"PB Bloland","year":"2001","unstructured":"Bloland PB. Drug resistance in malaria. Geneva: World Health Organization; 2001."},{"key":"3446_CR17","volume-title":"Anti-malarial drug efficacy and drug resistance","author":"WHO","year":"2018","unstructured":"WHO. Anti-malarial drug efficacy and drug resistance. Geneva: World Health Organization; 2018."},{"key":"3446_CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1368-7646(98)80208-2","volume":"1","author":"NJ White","year":"1998","unstructured":"White NJ. Preventing anti-malarial drug resistance through combinations. Drug Resist Updat. 1998;1:3\u20139.","journal-title":"Drug Resist Updat"},{"issue":"2 Suppl","key":"3446_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4269\/ajtmh.2004.71.179","volume":"71","author":"S Yeung","year":"2004","unstructured":"Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ. Anti-malarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg. 2004;71(2 Suppl):179\u201386.","journal-title":"Am J Trop Med Hyg"},{"key":"3446_CR20","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/S0140-6736(12)60484-X","volume":"379","author":"AP Phyo","year":"2012","unstructured":"Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960\u20136.","journal-title":"Lancet"},{"key":"3446_CR21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"3446_CR22","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/AAC.00686-12","volume":"57","author":"R Leang","year":"2013","unstructured":"Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother. 2013;57:818\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"3446_CR23","doi-asserted-by":"crossref","first-page":"e57689","DOI":"10.1371\/journal.pone.0057689","volume":"8","author":"MP Kyaw","year":"2013","unstructured":"Kyaw MP, Nyunt MH, Chit K, Aye MM, Aye KH, Aye MM, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS ONE. 2013;8:e57689.","journal-title":"PLoS ONE"},{"key":"3446_CR24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"3446_CR25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1473-3099(15)70032-0","volume":"15","author":"KM Tun","year":"2015","unstructured":"Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015;15:415\u201321.","journal-title":"Lancet Infect Dis"},{"key":"3446_CR26","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/1475-2875-13-286","volume":"13","author":"C Smith Gueye","year":"2014","unstructured":"Smith Gueye C, Newby G, Hwang J, Phillips AA, Whittaker M, MacArthur JR, et al. The challenge of artemisinin resistance can only be met by eliminating Plasmodium falciparum malaria across the Greater Mekong subregion. Malar J. 2014;13:286.","journal-title":"Malar J"},{"key":"3446_CR27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1473-3099(10)70214-0","volume":"11","author":"NK Shah","year":"2011","unstructured":"Shah NK, Dhillon GP, Dash AP, Arora U, Meshnick SR, Valecha N. Anti-malarial drug resistance of Plasmodium falciparum in India: changes over time and space. Lancet Infect Dis. 2011;11:57\u201364.","journal-title":"Lancet Infect Dis"},{"key":"3446_CR28","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12936-018-2290-9","volume":"17","author":"E Davlantes","year":"2018","unstructured":"Davlantes E, Dimbu PR, Ferreira CM, Florinda Joao M, Pode D, Felix J, et al. Efficacy and safety of artemether\u2013lumefantrine, artesunate\u2013amodiaquine, and dihydroartemisinin\u2013piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017. Malar J. 2018;17:144.","journal-title":"Malar J"},{"key":"3446_CR29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12936-019-2911-y","volume":"18","author":"J Raman","year":"2019","unstructured":"Raman J, Kagoro FM, Mabuza A, Malatje G, Reid A, Frean J, et al. Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18 years of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001\u20132018). Malar J. 2019;18:280.","journal-title":"Malar J"},{"key":"3446_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/JNSM.JNSM_71_19","volume":"3","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;3:1\u20137.","journal-title":"Nat Med"},{"key":"3446_CR31","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.48.6.2116-2123.2004","volume":"48","author":"ML Gatton","year":"2004","unstructured":"Gatton ML, Martin LB, Cheng Q. Evolution of resistance to sulfadoxine-pyrimethamine in Plasmodium falciparum. Antimicrob Agents Chemother. 2004;48:2116\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"3446_CR32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.meegid.2005.09.001","volume":"6","author":"G Holmgren","year":"2006","unstructured":"Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol. 2006;6:309\u201314.","journal-title":"Infect Genet Evol"},{"key":"3446_CR33","volume-title":"A study on the public health and socioeconomic impact of substandard and falsified medical products","author":"WHO","year":"2017","unstructured":"WHO. A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva: World Health Organization; 2017."},{"key":"3446_CR34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1046\/j.1365-3156.2002.00937.x","volume":"7","author":"PG Risha","year":"2002","unstructured":"Risha PG, Shewiyo D, Msami A, Masuki G, Vergote G, Vervaet C, et al. In vitro evaluation of the quality of essential drugs on the Tanzanian market. Trop Med Int Health. 2002;7:701\u20137.","journal-title":"Trop Med Int Health"},{"key":"3446_CR35","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3201\/eid1511.090886","volume":"15","author":"T Leslie","year":"2009","unstructured":"Leslie T, Kaur H, Mohammed N, Kolaczinski K, Ord RL, Rowland M. Epidemic of Plasmodium falciparum malaria involving substandard anti-malarial drugs, Pakistan, 2003. Emerg Infect Dis. 2009;15:1753\u20139.","journal-title":"Emerg Infect Dis"},{"key":"3446_CR36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/bcp.12298","volume":"78","author":"A Johnston","year":"2014","unstructured":"Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol. 2014;78:218\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"3446_CR37","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14787210.2016.1187560","volume":"14","author":"PN Newton","year":"2016","unstructured":"Newton PN, Caillet C, Guerin PJ. A link between poor quality anti-malarials and malaria drug resistance? Expert Rev Anti Infect Ther. 2016;14:531\u20133.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"3446_CR38","volume-title":"Methods for surveillance of anti-malarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of anti-malarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"3446_CR39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12916-015-0445-x","volume":"13","author":"P Dahal","year":"2015","unstructured":"Dahal P, d\u2019Alessandro U, Dorsey G, Guerin PJ, Nsanzabana C, Price RN, et al. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med. 2015;13:212.","journal-title":"BMC Med"},{"key":"3446_CR40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pt.2017.01.004","volume":"33","author":"AM Dondorp","year":"2017","unstructured":"Dondorp AM, Smithuis F, Woodrow C, von Seidlein L. How to contain artemisinin- and multidrug-resistant falciparum malaria. Trends Parasitol. 2017;33:353\u201363.","journal-title":"Trends Parasitol"},{"key":"3446_CR41","volume-title":"Global Technical strategy for malaria 2016\u20132030","author":"WHO","year":"2014","unstructured":"WHO. Global Technical strategy for malaria 2016\u20132030. Geneva: World Health Organization; 2014."},{"key":"3446_CR42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.19-0706","volume":"102","author":"J Takata","year":"2020","unstructured":"Takata J, Sondo P, Humphreys GS, Burrow R, Maguire B, Hossain MS, et al. The WWARN Clinical Trials Publication Library: a live, open-access database of Plasmodium treatment efficacy trials. Am J Trop Med Hyg. 2020;102:359\u201368.","journal-title":"Am J Trop Med Hyg"},{"key":"3446_CR43","volume-title":"Global Report on anti-malarial drug efficacy and drug resistance: 2000\u20132010","author":"WHO","year":"2010","unstructured":"WHO. Global Report on anti-malarial drug efficacy and drug resistance: 2000\u20132010. Geneva: World Health Organization; 2010."},{"key":"3446_CR44","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1128\/AAC.00835-15","volume":"59","author":"R Leang","year":"2015","unstructured":"Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"3446_CR45","doi-asserted-by":"crossref","first-page":"e53772","DOI":"10.1371\/journal.pone.0053772","volume":"8","author":"A Yeka","year":"2013","unstructured":"Yeka A, Tibenderana J, Achan J, D\u2019Alessandro U, Talisuna AO. Efficacy of quinine, artemether\u2013lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children. PLoS ONE. 2013;8:e53772.","journal-title":"PLoS ONE"},{"key":"3446_CR46","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/S2214-109X(16)30236-4","volume":"5","author":"HM Mavoko","year":"2017","unstructured":"Mavoko HM, Nabasumba C, da Luz RI, Tinto H, D\u2019Alessandro U, Kambugu A, et al. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial. Lancet Glob Health. 2017;5:e60\u20138.","journal-title":"Lancet Glob Health"},{"key":"3446_CR47","volume-title":"Anti-malarial drug combination therapy","author":"WHO","year":"2001","unstructured":"WHO. Anti-malarial drug combination therapy. Report of a WHO Technical Consultation. Geneva: World Health Organization; 2001."},{"key":"3446_CR48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1475-2875-5-48","volume":"5","author":"CH Sibley","year":"2006","unstructured":"Sibley CH, Ringwald P. A database of anti-malarial drug resistance. Malar J. 2006;5:48.","journal-title":"Malar J"},{"key":"3446_CR49","volume-title":"Parasite drug resistance","author":"WHO","year":"2018","unstructured":"WHO. Parasite drug resistance. Geneva: World Health Organization; 2018."},{"key":"3446_CR50","volume-title":"Global anti-malarial drug policy database Africa","author":"WHO","year":"2006","unstructured":"WHO. Global anti-malarial drug policy database Africa. Geneva: World Health Organization; 2006."},{"key":"3446_CR51","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1475-2875-11-140","volume":"11","author":"RA Khatib","year":"2012","unstructured":"Khatib RA, Skarbinski J, Njau JD, Goodman CA, Elling BF, Kahigwa E, et al. Routine delivery of artemisinin-based combination treatment at fixed health facilities reduces malaria prevalence in Tanzania: an observational study. Malar J. 2012;11:140.","journal-title":"Malar J"},{"key":"3446_CR52","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1360-2276.2003.01114.x","volume":"8","author":"East African Network for Monitoring Anti-malarial Treatment","year":"2003","unstructured":"East African Network for Monitoring Anti-malarial Treatment. The efficacy of anti-malarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health. 2003;8:860\u20137.","journal-title":"Trop Med Int Health"},{"key":"3446_CR53","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1046\/j.1365-3156.2001.00799.x","volume":"6","author":"East African Network for Monitoring Anti-malarial Treatment","year":"2001","unstructured":"East African Network for Monitoring Anti-malarial Treatment. Monitoring anti-malarial drug resistance within National Malaria Control Programmes: the EANMAT experience. Trop Med Int Health. 2001;6:891\u20138.","journal-title":"Trop Med Int Health"},{"key":"3446_CR54","volume-title":"AMI\/RAVREDA. Amazon malaria initiative\/Amazon network for surveillance of anti-malarial drug resistance. Ten years of malaria prevention and control in the region","author":"PAHO","year":"2011","unstructured":"PAHO. AMI\/RAVREDA. Amazon malaria initiative\/Amazon network for surveillance of anti-malarial drug resistance. Ten years of malaria prevention and control in the region. Panama City: Pan American Health Organization; 2011."},{"key":"3446_CR55","volume-title":"Fifth meeting of the Greater Mekong Subregion (GMS) therapeutic efficacy studies (TES) network","author":"WHO","year":"2017","unstructured":"WHO. Fifth meeting of the Greater Mekong Subregion (GMS) therapeutic efficacy studies (TES) network. Vietnam: World Health Organization; 2017."},{"key":"3446_CR56","unstructured":"Nugent R, Back E, Beith A. The race against drug resistance. Center for Global Development\u2019s Drug Resistance Working Group; 2010."},{"key":"3446_CR57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.12688\/wellcomeopenres.12259.1","volume":"2","author":"E Pisani","year":"2017","unstructured":"Pisani E, Botchway S. Sharing individual patient and parasite-level data through the WorldWide Anti-malarial Resistance Network platform: a qualitative case study. Wellcome Open Res. 2017;2:63.","journal-title":"Wellcome Open Res"},{"key":"3446_CR58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/1475-2875-6-119","volume":"6","author":"RN Price","year":"2007","unstructured":"Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, d\u2019Alessandro U, et al. World Anti-malarial Resistance Network I: clinical efficacy of anti-malarial drugs. Malar J. 2007;6:119.","journal-title":"Malar J"},{"key":"3446_CR59","unstructured":"WWARN. Clinical module: data management and statistical analysis plan version 1.2.; 2012."},{"key":"3446_CR60","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12936-017-2074-7","volume":"16","author":"P Dahal","year":"2017","unstructured":"Dahal P, Simpson JA, Dorsey G, Guerin PJ, Price RN, Stepniewska K. Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges. Malar J. 2017;16:430.","journal-title":"Malar J"},{"key":"3446_CR61","unstructured":"WWARN. Clinical Trials Publication Library 2020. https:\/\/www.wwarn.org\/tools-resources\/literature-reviews\/wwarn-clinical-trials-publication-library. Accessed 15 Oct 2020."},{"key":"3446_CR62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4103\/2229-3485.83221","volume":"2","author":"SK Gupta","year":"2011","unstructured":"Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2:109\u201312.","journal-title":"Perspect Clin Res"},{"key":"3446_CR63","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.5811\/westjem.2017.8.35985","volume":"18","author":"CE McCoy","year":"2017","unstructured":"McCoy CE. Understanding the intention-to-treat principle in randomized controlled trials. West J Emerg Med. 2017;18:1075\u20138.","journal-title":"West J Emerg Med"},{"key":"3446_CR64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/1475-2875-5-127","volume":"5","author":"K Stepniewska","year":"2006","unstructured":"Stepniewska K, White NJ. Some considerations in the design and interpretation of anti-malarial drug trials in uncomplicated falciparum malaria. Malar J. 2006;5:127.","journal-title":"Malar J"},{"key":"3446_CR65","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/ctg.2013.13","volume":"5","author":"AG Singal","year":"2014","unstructured":"Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5:e45.","journal-title":"Clin Transl Gastroenterol"},{"key":"3446_CR66","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-017-01352-3","volume":"8","author":"JD Challenger","year":"2017","unstructured":"Challenger JD, Bruxvoort K, Ghani AC, Okell LC. Assessing the impact of imperfect adherence to artemether\u2013lumefantrine on malaria treatment outcomes using within-host modelling. Nat Commun. 2017;8:1373.","journal-title":"Nat Commun"},{"key":"3446_CR67","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1056\/NEJMoa1606701","volume":"375","author":"PW Gething","year":"2016","unstructured":"Gething PW, Casey DC, Weiss DJ, Bisanzio D, Bhatt S, Cameron E, et al. Mapping Plasmodium falciparum mortality in Africa between 1990 and 2015. N Engl J Med. 2016;375:2435\u201345.","journal-title":"N Engl J Med"},{"key":"3446_CR68","unstructured":"MAP. High resolution interactive maps. Oxford: Malaria Atlas Project; 2019. https:\/\/malariaatlas.org\/explorer\/#\/. Accessed 15 Oct 2020."},{"key":"3446_CR69","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12936-015-0574-x","volume":"14","author":"DJ Weiss","year":"2015","unstructured":"Weiss DJ, Mappin B, Dalrymple U, Bhatt S, Cameron E, Hay SI, et al. Re-examining environmental correlates of Plasmodium falciparum malaria endemicity: a data-intensive variable selection approach. Malar J. 2015;14:68.","journal-title":"Malar J"},{"key":"3446_CR70","unstructured":"IHME. Institute of Health Metrics and Evaluation Data 2020. https:\/\/ghdx.healthdata.org\/ihme_data. Accessed 15 Oct 2020."},{"key":"3446_CR71","unstructured":"MAP. Malaria Covariates Oxford: Malaria Atlas Project; 2020. https:\/\/malariaatlas.org\/data-project\/covariates\/. Accessed 15 Oct 2020."},{"key":"3446_CR72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1475-2875-13-171","volume":"13","author":"DJ Weiss","year":"2014","unstructured":"Weiss DJ, Bhatt S, Mappin B, Van Boeckel TP, Smith DL, Hay SI, et al. Air temperature suitability for Plasmodium falciparum malaria transmission in Africa 2000\u20132012: a high-resolution spatiotemporal prediction. Malar J. 2014;13:171.","journal-title":"Malar J"},{"key":"3446_CR73","doi-asserted-by":"crossref","first-page":"e1000048","DOI":"10.1371\/journal.pmed.1000048","volume":"6","author":"SI Hay","year":"2009","unstructured":"Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, Noor AM, et al. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med. 2009;6:e1000048.","journal-title":"PLoS Med"},{"key":"3446_CR74","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-015-0372-x","volume":"13","author":"U Dalrymple","year":"2015","unstructured":"Dalrymple U, Mappin B, Gething PW. Malaria mapping: understanding the global endemicity of falciparum and vivax malaria. BMC Med. 2015;13:140.","journal-title":"BMC Med"},{"key":"3446_CR75","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.isprsjprs.2014.10.001","volume":"98","author":"DJ Weiss","year":"2014","unstructured":"Weiss DJ, Atkinson PM, Bhatt S, Mappin B, Hay SI, Gething PW. An effective approach for gap-filling continental scale remotely sensed time-series. ISPRS J Photogramm Remote Sens. 2014;98:106\u201318.","journal-title":"ISPRS J Photogramm Remote Sens"},{"key":"3446_CR76","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1475-2875-10-298","volume":"10","author":"AS Stensgaard","year":"2011","unstructured":"Stensgaard AS, Vounatsou P, Onapa AW, Simonsen PE, Pedersen EM, Rahbek C, et al. Bayesian geostatistical modelling of malaria and lymphatic filariasis infections in Uganda: predictors of risk and geographical patterns of co-endemicity. Malar J. 2011;10:298.","journal-title":"Malar J"},{"key":"3446_CR77","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2307\/1937887","volume":"49","author":"DE Farrar","year":"1967","unstructured":"Farrar DE, Glauber RR. Multicollinearity in regression analysis: the problem revisited. Rev Economics Stat. 1967;49:92\u2013107.","journal-title":"Rev Economics Stat"},{"key":"3446_CR78","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1467-9868.2008.00700.x","volume":"71","author":"H Rue","year":"2009","unstructured":"Rue H, Martino S, Chopin N. Approximate Bayesian inference for latent Gaussian models using integrated nested Laplace approximations. J R Stat Soc B. 2009;71:319\u201392.","journal-title":"J R Stat Soc B"},{"key":"3446_CR79","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1467-9868.2008.00663.x","volume":"70","author":"S Banerjee","year":"2008","unstructured":"Banerjee S, Gelfand AE, Finley AO, Sang H. Gaussian predictive process models for large spatial data sets. J R Stat Soc B. 2008;70:825\u201348.","journal-title":"J R Stat Soc B"},{"key":"3446_CR80","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.sste.2013.07.003","volume":"7","author":"M Blangiardo","year":"2013","unstructured":"Blangiardo M, Cameletti M, Baio G, Rue H. Spatial and spatio-temporal models with R-INLA. Spat Spatiotemporal Epidemiol. 2013;7:39\u201355.","journal-title":"Spat Spatiotemporal Epidemiol"},{"key":"3446_CR81","first-page":"1","volume":"32","author":"D Simpson","year":"2017","unstructured":"Simpson D, Rue H, Riebler A, Martins TG, S\u00f8rbye SH. Penalising model component complexity: a principled, practical approach to constructing priors. Stat Sci. 2017;32:1\u201328.","journal-title":"Stat Sci"},{"key":"3446_CR82","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc B. 2002;64:583\u2013639.","journal-title":"J R Stat Soc B."},{"key":"3446_CR83","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1541-0420.2009.01191.x","volume":"65","author":"C Czado","year":"2009","unstructured":"Czado C, Gneiting T, Held L. Predictive model assessment for count data. Biometrics. 2009;65:1254\u201361.","journal-title":"Biometrics"},{"key":"3446_CR84","doi-asserted-by":"crossref","first-page":"29628","DOI":"10.1038\/srep29628","volume":"6","author":"VA Alegana","year":"2016","unstructured":"Alegana VA, Atkinson PM, Lourenco C, Ruktanonchai NW, Bosco C, Erbach-Schoenberg EZ, et al. Advances in mapping malaria for elimination: fine resolution modelling of Plasmodium falciparum incidence. Sci Rep. 2016;6:29628.","journal-title":"Sci Rep"},{"key":"3446_CR85","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.2517-6161.1990.tb01780.x","volume":"B","author":"LI Pettit","year":"1990","unstructured":"Pettit LI. The conditional predictive ordinate for the normal distribution. J R Statist Soc. 1990;B:175\u201384.","journal-title":"J R Statist Soc."},{"key":"3446_CR86","volume-title":"Model determination using predictive distirbutions with the implementation via sampling-based methods","author":"AE Gelfand","year":"1992","unstructured":"Gelfand AE, Dey DK, Chang H. Model determination using predictive distirbutions with the implementation via sampling-based methods. Stanford: Department of Statistics, Stanford University; 1992."},{"key":"3446_CR87","first-page":"278","volume":"147","author":"AP Dawid","year":"1984","unstructured":"Dawid AP. Statistical theory: the prequential approach (with discussion). J R Statist Soc. 1984;147:278\u201392.","journal-title":"J R Statist Soc"},{"key":"3446_CR88","doi-asserted-by":"crossref","first-page":"e181662","DOI":"10.1001\/jamanetworkopen.2018.1662","volume":"1","author":"S Ozawa","year":"2018","unstructured":"Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, et al. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: a systematic review and meta-analysis. JAMA Netw Open. 2018;1:e181662.","journal-title":"JAMA Netw Open"},{"key":"3446_CR89","first-page":"659","volume-title":"Resistance in human malaria IV: 4-aminoquinolines and multiple resistance. Chemotherapy and drug resistance in malaria","author":"W Peters","year":"1987","unstructured":"Peters W. Resistance in human malaria IV: 4-aminoquinolines and multiple resistance. Chemotherapy and drug resistance in malaria. London: London Academic Press; 1987. p. 659\u2013786."},{"key":"3446_CR90","volume-title":"Position of WHO's Roll Back Malaria Department on malaria treatment policy","author":"WHO","year":"2003","unstructured":"WHO. Position of WHO\u2019s Roll Back Malaria Department on malaria treatment policy. Geneva: World Health Organization; 2003."},{"key":"3446_CR91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1475-2875-7-29","volume":"7","author":"B Wasunna","year":"2008","unstructured":"Wasunna B, Zurovac D, Goodman CA, Snow RW. Why don\u2019t health workers prescribe ACT? A qualitative study of factors affecting the prescription of artemether\u2013lumefantrine. Malar J. 2008;7:29.","journal-title":"Malar J"},{"key":"3446_CR92","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1475-2875-8-174","volume":"8","author":"C Sayang","year":"2009","unstructured":"Sayang C, Gausseres M, Vernazza-Licht N, Malvy D, Bley D, Millet P. Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in rural health facilities in southern Cameroon. Malar J. 2009;8:174.","journal-title":"Malar J"},{"key":"3446_CR93","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12936-018-2332-3","volume":"17","author":"NY Ntamabyaliro","year":"2018","unstructured":"Ntamabyaliro NY, Burri C, Nzolo DB, Engo AB, Lula YN, Mampunza SM, et al. Drug use in the management of uncomplicated malaria in public health facilities in the Democratic Republic of the Congo. Malar J. 2018;17:189.","journal-title":"Malar J"},{"key":"3446_CR94","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41182-018-0096-7","volume":"46","author":"DH Rakotonandrasana","year":"2018","unstructured":"Rakotonandrasana DH, Tsukahara T, Yamamoto-Mitani N. Anti-malarial drug prescribing by healthcare workers when malaria testing is negative: a qualitative study in Madagascar. Trop Med Health. 2018;46:13.","journal-title":"Trop Med Health"},{"key":"3446_CR95","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/1475-2875-11-290","volume":"11","author":"D Parker","year":"2012","unstructured":"Parker D, Lerdprom R, Srisatjarak W, Yan G, Sattabongkot J, Wood J, et al. Longitudinal in vitro surveillance of Plasmodium falciparum sensitivity to common anti-malarials in Thailand between 1994 and 2010. Malar J. 2012;11:290.","journal-title":"Malar J"},{"key":"3446_CR96","volume-title":"Roll Back Malaria. World malaria report 2005","author":"WHO","year":"2005","unstructured":"WHO. Roll Back Malaria. World malaria report 2005. Geneva: World Health Organization; 2005."},{"key":"3446_CR97","volume-title":"World malaria report 2010","author":"WHO","year":"2010","unstructured":"WHO. World malaria report 2010. Geneva: World Health Organization; 2010."},{"key":"3446_CR98","doi-asserted-by":"crossref","first-page":"e42284","DOI":"10.1371\/journal.pone.0042284","volume":"7","author":"MK Laufer","year":"2012","unstructured":"Laufer MK, Thesing PC, Dzinjalamala FK, Nyirenda OM, Masonga R, Laurens MB, et al. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria. PLoS ONE. 2012;7:e42284.","journal-title":"PLoS ONE"},{"key":"3446_CR99","doi-asserted-by":"crossref","first-page":"e01068","DOI":"10.1128\/AAC.01068-18","volume":"62","author":"S Dini","year":"2018","unstructured":"Dini S, Zaloumis S, Cao P, Price RN, Fowkes FJI, van der Pluijm RW, et al. Investigating the efficacy of triple artemisinin-based combination therapies for treating Plasmodium falciparum malaria patients using mathematical modeling. Antimicrob Agents Chemother. 2018;62:e01068-e1118.","journal-title":"Antimicrob Agents Chemother"},{"key":"3446_CR100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/tropicalmed4010026","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.","journal-title":"Trop Med Infect Dis"},{"key":"3446_CR101","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1473-3099(18)30068-9","volume":"18","author":"R Amato","year":"2018","unstructured":"Amato R, Pearson RD, Almagro-Garcia J, Amaratunga C, Lim P, Suon S, et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis. 2018;18:337\u201345.","journal-title":"Lancet Infect Dis"},{"key":"3446_CR102","doi-asserted-by":"crossref","first-page":"e0127818","DOI":"10.1371\/journal.pone.0127818","volume":"10","author":"K Galactionova","year":"2015","unstructured":"Galactionova K, Tediosi F, de Savigny D, Smith T, Tanner M. Effective coverage and systems effectiveness for malaria case management in sub-Saharan African countries. PLoS ONE. 2015;10:e0127818.","journal-title":"PLoS ONE"},{"key":"3446_CR103","volume-title":"Human development report 2011. Sustainability and equity: a better future for all","author":"UNDP","year":"2011","unstructured":"UNDP. Human development report 2011. Sustainability and equity: a better future for all. New York: UN Development Programme; 2011."},{"key":"3446_CR104","volume-title":"The potential impact of health service disruptions on the burden of malaria","author":"WHO","year":"2020","unstructured":"WHO. The potential impact of health service disruptions on the burden of malaria. Geneva: World Health Organization; 2020."},{"key":"3446_CR105","doi-asserted-by":"crossref","unstructured":"Cui L, Cao Y, Kaewkungwal J, Khamsiriwatchara A, Lawpoolsri S, Soe TN, et al. Malaria elimination in the Greater Mekong Subregion: challenges and prospects. Towards malaria elimination\u2014a leap forward. In: Manguin S, Dev V, editors. Towards malaria elimination. InTechOpen Publ; 2018.","DOI":"10.5772\/intechopen.76337"},{"key":"3446_CR106","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.actatropica.2011.02.016","volume":"121","author":"L Cui","year":"2012","unstructured":"Cui L, Yan G, Sattabongkot J, Cao Y, Chen B, Chen X, et al. Malaria in the Greater Mekong Subregion: heterogeneity and complexity. Acta Trop. 2012;121:227\u201339.","journal-title":"Acta Trop"},{"issue":"Suppl 1","key":"3446_CR107","first-page":"46","volume":"44","author":"S Hewitt","year":"2013","unstructured":"Hewitt S, Delacollette C, Chavez I. Malaria situation in the Greater Mekong Subregion. Southeast Asian J Trop Med Public Health. 2013;44(Suppl 1):46\u201372.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"3446_CR108","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12936-015-0921-y","volume":"14","author":"DM Parker","year":"2015","unstructured":"Parker DM, Carrara VI, Pukrittayakamee S, McGready R, Nosten FH. Malaria ecology along the Thailand-Myanmar border. Malar J. 2015;14:388.","journal-title":"Malar J"},{"key":"3446_CR109","first-page":"819","volume":"43","author":"J Xu","year":"2012","unstructured":"Xu J, Liu H. The challenges of malaria elimination in Yunnan Province, People\u2019s Republic of China. Southeast Asian J Trop Med Public Health. 2012;43:819\u201324.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"3446_CR110","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/1475-2875-12-374","volume":"12","author":"H Pasquale","year":"2013","unstructured":"Pasquale H, Jarvese M, Julla A, Doggale C, Sebit B, Lual MY, et al. Malaria control in South Sudan, 2006\u20132013: strategies, progress and challenges. Malar J. 2013;12:374.","journal-title":"Malar J"},{"key":"3446_CR111","first-page":"1493","volume":"25","author":"BE van den Borne","year":"1998","unstructured":"van den Borne BE, Landewe RB, Goei The HS, Rietveld JH, Zwinderman AH, Bruyn GA, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol. 1998;25:1493\u20138.","journal-title":"J Rheumatol"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-020-03446-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03446-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T04:14:27Z","timestamp":1723781667000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03446-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3446"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03446-8","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"7 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"374"}}